{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:09:10Z","timestamp":1788030550724,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40257-022-00738-4","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T08:03:20Z","timestamp":1670918600000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct03720470","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sonja","family":"St\u00e4nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Rojo","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"1","key":"738_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"738_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"738_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13555-021-00488-x","volume":"11","author":"AW Vilsb\u00f8ll","year":"2021","unstructured":"Vilsb\u00f8ll AW, Anderson P, Piercy J, Milligan G, Kragh N. Extent and impact of inadequate disease control in us adults with a history of moderate to severe atopic dermatitis following introduction of new treatments. Dermatol Ther (Heidelb). 2021;11(2):475\u201386.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"738_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41232-017-0044-7","volume":"37","author":"P Rerknimitr","year":"2017","unstructured":"Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14.","journal-title":"Inflamm Regen."},{"issue":"9","key":"738_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"738_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","volume":"11","author":"T Buhl","year":"2021","unstructured":"Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Pe\u00f1as P, Igarashi A, Konstantinou MP, et al. Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 phase 3 studies. Dermatol Ther (Heidelb). 2021;11(3):971\u201382.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3, Supplement","key":"738_CR7","doi-asserted-by":"publisher","first-page":"AB171","DOI":"10.1016\/j.jaad.2021.06.697","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Ardern-Jones MR, Bieber T, Hong CH, Chu CY, Liu M, et al. 28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up). J Am Acad Dermatol. 2021;85(3, Supplement):AB171.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"738_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","volume":"82","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"738_CR9","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.25251\/skin.5.supp.61","volume":"5","author":"E Simpson","year":"2021","unstructured":"Simpson E, Wollenberg A, Soong W, Mark T, Kuznetsova A, Abildgaard Steffensen L, et al. Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2. SKIN J Cutan Med. 2021;5(6):S61.","journal-title":"SKIN J Cutan Med."},{"key":"738_CR10","unstructured":"CIBINQO 100 mg film-coated tablets. Summary of product characteristics. Pfizer, Limited: Kent; 2021. Updated September 10, 2021."},{"key":"738_CR11","unstructured":"European Medicines Agency. CIBINQO\u00ae (abrocitinib). Summary of product characteristics. Beligium: Pfizer Europe MA EEIG; 2021."},{"key":"738_CR12","unstructured":"JAPAN\u2019S MHLW approves Pfizer's CIBINQO\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis. News release. Pfizer Inc.; 2021."},{"key":"738_CR13","unstructured":"CIBINQO (abrocitinib) tablets, for oral use. Prescribing information. New York: Pfizer Inc.; 2022."},{"issue":"10246","key":"738_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"738_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"738_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"738_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40271-019-00373-y","volume":"12","author":"A Barrett","year":"2019","unstructured":"Barrett A, Hanh-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445\u201359.","journal-title":"Patient"},{"key":"738_CR18","first-page":"1","volume":"2","author":"M Boeri","year":"2020","unstructured":"Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, Di Bonaventura M. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatol Treat. 2020;2:1\u201310.","journal-title":"J Dermatol Treat"},{"key":"738_CR19","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"5","key":"738_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/ced.14567","volume":"46","author":"AM Cartron","year":"2021","unstructured":"Cartron AM, Nguyen TH, Roh YS, Kwatra MM, Kwatra SG. JAK inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"738_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","volume":"86","author":"N Sutaria","year":"2022","unstructured":"Sutaria N, Adawi W, Goldberg R, Roh YS, Choi J, Kwatra SG. Itch: pathogenesis and treatment. J Am Acad Dermatol. 2022;86(1):17\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"738_CR22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"738_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/jdv.15480","volume":"33","author":"YA Leshem","year":"2019","unstructured":"Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, et al. Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. J Eur Acad Dermatol Venereol. 2019;33(5):807\u201315.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00738-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T13:13:08Z","timestamp":1675343588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00738-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"17 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SS is an investigator for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Novartis, Sanofi Genzyme, Trevi Therapeutics, and Vanda; a member of scientific advisory boards, consultant, and\/or speaker for Pfizer Inc., AbbVie, Almirall, Beiersdorf, Bellus Health, Benevolent, Bionorica, Cara, Clexio, Eli Lilly, Escient, Galderma, Gr\u00fcnenthal, Kiniksa, LEO Pharma, Menlo Therapeutics, P.G. Unna Academy, Sanofi Genzyme, Trevi Therapeutics, and Vifor. SGK is an advisory board member\/consultant for\u00a0Pfizer Inc., AbbVie, Celldex Therapeutics, Galderma, Incyte Corporation, Kiniksa Pharmaceuticals, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, and Sanofi Genzyme; and has served as an investigator for Pfizer Inc.,\u00a0Galderma, Kiniksa Pharmaceuticals, and Sanofi Genzyme. JIS has served as an investigator for Celgene, Eli Lilly, F. Hoffmann-La\u00a0Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron, and Sanofi Genzyme; as a consultant for Pfizer Inc.,\u00a0AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. ELS has received grants from Pfizer Inc.,\u00a0Eli Lilly, Kyowa Kirin, LEO Pharma, Merck, and Regeneron Pharmaceuticals and personal fees from Pfizer Inc.,\u00a0Bausch Health (Valeant), Dermira, Eli Lilly, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron, and Sanofi Genzyme. JPT is an advisor for Pfizer Inc.,\u00a0AbbVie, Almirall, Arena Pharmaceuticals, Aslan Pharmaceuticals, Eli Lilly, LEO Pharma, OM Pharma, Regeneron Pharmaceuticals, Sanofi Genzyme, and Union Therapeutics; a speaker for Pfizer Inc.,\u00a0AbbVie, Almirall, Eli Lilly, LEO Pharma, Regeneron Pharmaceuticals, and Sanofi Genzyme; and received research grants from Pfizer Inc., Regeneron Pharmaceuticals, and Sanofi Genzyme. GY has been a consultant and an advisor for Pfizer Inc.,\u00a0Bellus, Eli Lilly, Galderma, Kiniksa, LEO Pharma, Novartis, Sanofi\u00a0Regeneron, and Trevi Therapeutics and a principal investigator for Pfizer Inc.,\u00a0Galderma, Kiniksa, LEO Pharma, and Sanofi Regeneron. HV, MDB, and CF are employees and shareholders of Pfizer Inc. FZ and RRC are former employees and shareholders of Pfizer Inc. MC is a former employee and shareholder of Pfizer Inc.\u00a0and has been a speaker, member of scientific advisory boards, and\/or a consultant for AbbVie, Eli Lilly, and Incyte.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonization Good Clinical Practice guidelines. All local regulatory requirements were followed. This research was approved by the institutional review board or ethics committee at each trial site. This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See  for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"SS, JIS, ELS, JPT, GY, MCC, RRC, HV, and CF contributed to the study conception and design. FZ performed the data acquisition and analysis. All authors contributed to the data interpretation, had full editorial control of the manuscript, and provided input and approval of all drafts, including the final submitted version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}